Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC14 in Motor Neurone Disease
NCT03487263Phase 1Completed
- Sponsor
- Implicit Bioscience
- Start
- Oct 2017
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of atibuclimab in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Implicit Bioscience. Primary endpoint: Incidence of treatment-emergent adverse events at 1 month. Started Oct 2017; status: completed.
02
Drugs
atibuclimab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03487263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03487263.